S. 4987, Transparency and Oversight Mandate. Quorum's AI analysis reads it as a net benefit — and names who gains.
S. 4987 · Net good
What it does
This bill requires the Federal Trade Commission to produce annual reports on foreign investment in U.S. pharmaceutical companies, drug manufacturing, and DNA sequencing/storage technology.
The analysis did not isolate a single beneficiary class.
The trade-off
Annual reporting may create a de facto registry of foreign pharmaceutical ownership, potentially informing future CFIUS (Committee on Foreign Investment in the US) enforcement or legislative restrictions without explicitly authorizing them.
Transparency scores 78%, with a medium warning level and no detached riders.
Who is behind it
Filed by Elizabeth Warren. Cosponsored by Kirsten Gillibrand and Rick Scott.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.